Does the media refer more to FDMT or PHVS?

In the previous week, 4D Molecular Therapeutics had 7 more articles in the media than Pharvaris. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 3 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.54 beat 4D Molecular Therapeutics' score of 0.90 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer PVLA or FDMT?

In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than Palvella Therapeutics. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 9 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 1.03 beat 4D Molecular Therapeutics' score of 0.90 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to FDMT or MESO?

In the previous week, 4D Molecular Therapeutics had 7 more articles in the media than Mesoblast. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 3 mentions for Mesoblast. 4D Molecular Therapeutics' average media sentiment score of 0.90 beat Mesoblast's score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to FDMT or MLYS?

In the previous week, 4D Molecular Therapeutics had 4 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 6 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.00 beat 4D Molecular Therapeutics' score of 0.90 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

4D Molecular Therapeutics (FDMT) Competitors

$9.90 -0.28 (-2.75%)

As of 01:13 PM Eastern

Compare

FDMT vs. PHVS, PVLA, MESO, MLYS, and IOVA

Should you buy 4D Molecular Therapeutics stock or one of its competitors? MarketBeat compares 4D Molecular Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 4D Molecular Therapeutics include Pharvaris (PHVS), Palvella Therapeutics (PVLA), Mesoblast (MESO), Mineralys Therapeutics (MLYS), and Iovance Biotherapeutics (IOVA).

How does 4D Molecular Therapeutics compare to Pharvaris?

4D Molecular Therapeutics (NASDAQ:FDMT) and Pharvaris (NASDAQ:PHVS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

4D Molecular Therapeutics presently has a consensus target price of $30.67, indicating a potential upside of 209.92%. Pharvaris has a consensus target price of $50.08, indicating a potential upside of 55.85%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by insiders. Comparatively, 11.8% of Pharvaris shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

4D Molecular Therapeutics has a beta of 2.7, indicating that its share price is 170% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.34, indicating that its share price is 334% less volatile than the broader market.

In the previous week, 4D Molecular Therapeutics had 7 more articles in the media than Pharvaris. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 3 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.54 beat 4D Molecular Therapeutics' score of 0.90 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Pharvaris has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Pharvaris	N/A	-67.56%	-61.13%

4D Molecular Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$88.24M	5.86	-$140.11M	-$2.57	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A

Summary

4D Molecular Therapeutics beats Pharvaris on 11 of the 15 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Palvella Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 17.2% of Palvella Therapeutics shares are held by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Palvella Therapeutics has a beta of -0.17, suggesting that its stock price is 117% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.7, suggesting that its stock price is 170% more volatile than the broader market.

In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than Palvella Therapeutics. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 9 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 1.03 beat 4D Molecular Therapeutics' score of 0.90 indicating that Palvella Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
4D Molecular Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palvella Therapeutics presently has a consensus price target of $199.53, indicating a potential upside of 41.60%. 4D Molecular Therapeutics has a consensus price target of $30.67, indicating a potential upside of 209.92%. Given 4D Molecular Therapeutics' higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Palvella Therapeutics has higher earnings, but lower revenue than 4D Molecular Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	47.20	-$41.72M	-$4.17	N/A
4D Molecular Therapeutics	$88.24M	5.86	-$140.11M	-$2.57	N/A

Palvella Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

Summary

4D Molecular Therapeutics beats Palvella Therapeutics on 9 of the 17 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Mesoblast?

4D Molecular Therapeutics (NASDAQ:FDMT) and Mesoblast (NASDAQ:MESO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, 4D Molecular Therapeutics had 7 more articles in the media than Mesoblast. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 3 mentions for Mesoblast. 4D Molecular Therapeutics' average media sentiment score of 0.90 beat Mesoblast's score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4D Molecular Therapeutics currently has a consensus target price of $30.67, indicating a potential upside of 209.92%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe 4D Molecular Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

4D Molecular Therapeutics has a beta of 2.7, indicating that its stock price is 170% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

Mesoblast has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. Mesoblast's return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Mesoblast	N/A	N/A	N/A

Mesoblast has lower revenue, but higher earnings than 4D Molecular Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$88.24M	5.86	-$140.11M	-$2.57	N/A
Mesoblast	$17.20M	108.21	-$102.14M	-$0.28	N/A

Summary

4D Molecular Therapeutics beats Mesoblast on 9 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Mineralys Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Mineralys Therapeutics (NASDAQ:MLYS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

4D Molecular Therapeutics has a beta of 2.7, meaning that its share price is 170% more volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Mineralys Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. Mineralys Therapeutics' return on equity of -27.92% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

4D Molecular Therapeutics has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$88.24M	5.86	-$140.11M	-$2.57	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

4D Molecular Therapeutics currently has a consensus price target of $30.67, indicating a potential upside of 209.92%. Mineralys Therapeutics has a consensus price target of $49.33, indicating a potential upside of 93.53%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe 4D Molecular Therapeutics is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, 4D Molecular Therapeutics had 4 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 6 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.00 beat 4D Molecular Therapeutics' score of 0.90 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mineralys Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

4D Molecular Therapeutics beats Mineralys Therapeutics on 10 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Iovance Biotherapeutics presently has a consensus price target of $8.43, indicating a potential upside of 95.29%. 4D Molecular Therapeutics has a consensus price target of $30.67, indicating a potential upside of 209.92%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

4D Molecular Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	7.31	-$390.98M	-$0.95	N/A
4D Molecular Therapeutics	$88.24M	5.86	-$140.11M	-$2.57	N/A

In the previous week, 4D Molecular Therapeutics had 2 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 8 mentions for Iovance Biotherapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.90 beat Iovance Biotherapeutics' score of 0.22 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
4D Molecular Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Iovance Biotherapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.7, indicating that its stock price is 170% more volatile than the broader market.

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Iovance Biotherapeutics has a net margin of -123.92% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

Summary

4D Molecular Therapeutics beats Iovance Biotherapeutics on 13 of the 17 factors compared between the two stocks.

Get 4D Molecular Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FDMT vs. The Competition

Export

Metric	4D Molecular Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$517.27M	$3.51B	$6.80B	$12.67B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-3.85	7.37	282.15	25.05
Price / Sales	5.86	1,199.53	571.19	79.42
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	1.12	16.86	11.03	6.18
Net Income	-$140.11M	-$12.56M	$3.49B	$347.72M
7 Day Performance	-4.67%	-1.04%	0.31%	0.64%
1 Month Performance	-23.88%	-7.80%	-4.41%	-3.82%
1 Year Performance	54.13%	48.79%	62.76%	20.08%

4D Molecular Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FDMT 4D Molecular Therapeutics	3.5335 of 5 stars	$9.90 -2.8%	$30.67 +209.9%	+58.6%	$517.27M	$88.24M	N/A	120	News Coverage Upcoming Earnings Analyst Forecast
PHVS Pharvaris	3.757 of 5 stars	$33.55 -4.0%	$50.08 +49.3%	+63.1%	$2.29B	N/A	N/A	30	Positive News
PVLA Palvella Therapeutics	3.6031 of 5 stars	$124.15 -21.0%	$199.53 +60.7%	+280.4%	$2.26B	$42.81M	N/A	N/A	Positive News Upcoming Earnings
MESO Mesoblast	0.3337 of 5 stars	$16.63 -4.0%	N/A	-6.6%	$2.24B	$17.20M	N/A	80
MLYS Mineralys Therapeutics	3.6955 of 5 stars	$26.71 -1.4%	$49.33 +84.7%	+86.8%	$2.23B	N/A	N/A	28	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FDMT) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

4D Molecular Therapeutics (FDMT) Competitors

FDMT vs. PHVS, PVLA, MESO, MLYS, and IOVA

How does 4D Molecular Therapeutics compare to Pharvaris?

Summary

How does 4D Molecular Therapeutics compare to Palvella Therapeutics?

Summary

How does 4D Molecular Therapeutics compare to Mesoblast?

Summary

How does 4D Molecular Therapeutics compare to Mineralys Therapeutics?

Summary

How does 4D Molecular Therapeutics compare to Iovance Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT vs. The Competition

4D Molecular Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

4D Molecular Therapeutics (FDMT) Competitors

FDMT vs. PHVS, PVLA, MESO, MLYS, and IOVA

How does 4D Molecular Therapeutics compare to Pharvaris?

Do analysts prefer FDMT or PHVS?

Do insiders and institutionals believe in FDMT or PHVS?

Which has more risk and volatility, FDMT or PHVS?

Does the media refer more to FDMT or PHVS?

Is FDMT or PHVS more profitable?

Which has stronger earnings and valuation, FDMT or PHVS?

Summary

How does 4D Molecular Therapeutics compare to Palvella Therapeutics?

Do insiders and institutionals believe in PVLA or FDMT?

Which has more volatility & risk, PVLA or FDMT?

Does the media prefer PVLA or FDMT?

Do analysts rate PVLA or FDMT?

Which has better earnings & valuation, PVLA or FDMT?

Is PVLA or FDMT more profitable?

Summary

How does 4D Molecular Therapeutics compare to Mesoblast?

Do insiders and institutionals believe in FDMT or MESO?

Does the media refer more to FDMT or MESO?

Do analysts rate FDMT or MESO?

Which has more risk & volatility, FDMT or MESO?

Is FDMT or MESO more profitable?

Which has higher valuation & earnings, FDMT or MESO?

Summary

How does 4D Molecular Therapeutics compare to Mineralys Therapeutics?

Which has more risk and volatility, FDMT or MLYS?

Is FDMT or MLYS more profitable?

Which has preferable earnings and valuation, FDMT or MLYS?

Do analysts recommend FDMT or MLYS?

Do insiders & institutionals have more ownership in FDMT or MLYS?

Does the media refer more to FDMT or MLYS?

Summary

How does 4D Molecular Therapeutics compare to Iovance Biotherapeutics?

Do analysts prefer IOVA or FDMT?

Which has higher valuation & earnings, IOVA or FDMT?

Does the media prefer IOVA or FDMT?

Which has more risk and volatility, IOVA or FDMT?

Do institutionals and insiders have more ownership in IOVA or FDMT?

Is IOVA or FDMT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT vs. The Competition

4D Molecular Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools